These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21511279)

  • 61. Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth.
    Cha TL; Chuang MJ; Tang SH; Wu ST; Sun KH; Chen TT; Sun GH; Chang SY; Yu CP; Ho JY; Liu SY; Huang SM; Yu DS
    Mol Carcinog; 2015 Mar; 54(3):167-77. PubMed ID: 24115089
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Promoter methylation and expression of Runx3 gene in gastric cancer].
    Li LY; Li JK; Shen Y; Yu L; Zhang JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):379-82. PubMed ID: 18636364
    [TBL] [Abstract][Full Text] [Related]  

  • 63. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
    Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
    Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Demethylation of RUNX3 by vincristine in colorectal adenocarcinoma cells.
    Moon JW; Lee SK; Lee JO; Kim JH; Kim N; Kim J; Kim HS; Park SH
    Anticancer Res; 2014 Jan; 34(1):133-40. PubMed ID: 24403453
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
    Wada M; Yazumi S; Takaishi S; Hasegawa K; Sawada M; Tanaka H; Ida H; Sakakura C; Ito K; Ito Y; Chiba T
    Oncogene; 2004 Mar; 23(13):2401-7. PubMed ID: 14743205
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors.
    Glaser AP; Procissi D; Yu Y; Meeks JJ
    J Vis Exp; 2019 Mar; (145):. PubMed ID: 30985757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nicotinamide metabolism alterations in bladder cancer: Preliminary studies.
    Mierzejewska P; Gawlik-Jakubczak T; Jablonska P; Czajkowski M; Kutryb-Zajac B; Smolenski RT; Matuszewski M; Slominska EM
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):687-695. PubMed ID: 30663499
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Consecutive epigenetically-active agent combinations act in
    Sayar H; Liu Y; Gao R; Zaid MA; Cripe LD; Weisenbach J; Sargent KJ; Nassiri M; Li L; Konig H; Suvannasankha A; Pan F; Shanmugam R; Goswami C; Kapur R; Xu M; Boswell HS
    Oncotarget; 2018 Jan; 9(5):5703-5715. PubMed ID: 29464028
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular mechanism and therapeutic potential of HDAC9 in intervertebral disc degeneration.
    Lei M; Lin H; Shi D; Hong P; Song H; Herman B; Liao Z; Yang C
    Cell Mol Biol Lett; 2023 Dec; 28(1):104. PubMed ID: 38093179
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent.
    Jung M; Lee KM; Im Y; Seok SH; Chung H; Kim DY; Han D; Lee CH; Hwang EH; Park SY; Koh J; Kim B; Nikas IP; Lee H; Hwang D; Ryu HS
    Mol Oncol; 2022 May; 16(9):1795-1815. PubMed ID: 35278276
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283.
    ; Turck D; Bohn T; Castenmiller J; De Henauw S; Hirsch-Ernst KI; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Siani A; Thies F; Tsabouri S; Vinceti M; Cubadda F; Frenzel T; Heinonen M; Prieto Maradona M; Marchelli R; Neuhäuser-Berthold M; Poulsen M; Schlatter JR; van Loveren H; Albert O; de Sesmaisons Lecarré A; Knutsen HK
    EFSA J; 2021 Nov; 19(11):e06843. PubMed ID: 34804232
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Runt-related Transcription Factor 3 Promoter Hypermethylation and Gastric Cancer Risk: A Meta-analysis.
    Lina M; Changan W; Qing Z
    Open Life Sci; 2018 Jan; 13():64-70. PubMed ID: 33817069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment.
    Hwang ES; Song SB
    Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365524
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistochemistry and clinical value of sirtuin 2 in non-metastasized non-small cell lung cancer.
    Gao CX; Chen B; Xie HK; Han CN; Luo J
    J Thorac Dis; 2019 Sep; 11(9):3973-3979. PubMed ID: 31656671
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.
    Song SB; Park JS; Chung GJ; Lee IH; Hwang ES
    Metabolomics; 2019 Oct; 15(10):137. PubMed ID: 31587111
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.
    Jing H; Hu J; He B; Negrón Abril YL; Stupinski J; Weiser K; Carbonaro M; Chiang YL; Southard T; Giannakakou P; Weiss RS; Lin H
    Cancer Cell; 2016 Mar; 29(3):297-310. PubMed ID: 26977881
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.
    Liu Y; Yin T; Feng Y; Cona MM; Huang G; Liu J; Song S; Jiang Y; Xia Q; Swinnen JV; Bormans G; Himmelreich U; Oyen R; Ni Y
    Quant Imaging Med Surg; 2015 Oct; 5(5):708-29. PubMed ID: 26682141
    [TBL] [Abstract][Full Text] [Related]  

  • 78. How do K-RAS-activated cells evade cellular defense mechanisms?
    Lee YS; Bae SC
    Oncogene; 2016 Feb; 35(7):827-32. PubMed ID: 25961920
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The RUNX family: developmental regulators in cancer.
    Ito Y; Bae SC; Chuang LS
    Nat Rev Cancer; 2015 Feb; 15(2):81-95. PubMed ID: 25592647
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma.
    Itzhaki O; Greenberg E; Shalmon B; Kubi A; Treves AJ; Shapira-Frommer R; Avivi C; Ortenberg R; Ben-Ami E; Schachter J; Besser MJ; Markel G
    PLoS One; 2013; 8(2):e57160. PubMed ID: 23451174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.